Creyon Bio, Inc. (Creyon) has entered a global licensing and multi-target research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases.  As a part of the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly’s named targets on time scales not previously achievabl...